Fidaxomicin

12/01/2018 - "In the recurrent Clostridium difficile infection (rCDI) subgroup, fidaxomicin was 63% effective with three patients dying (15.7%) and two patients developing subsequent rCDI. "
03/01/2013 - "Fidaxomicin is a novel treatment for Clostridium difficile infections (CDIs). "
02/01/2012 - "Fidaxomicin, a new treatment for Clostridium difficile infections."
02/01/2017 - "The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort."
09/01/2015 - "Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model."

02/01/2019 - "The most important agreements were: recurrence is a risk criterion per se; fidaxomicin is effective and safe for the treatment of infections caused by C. "
12/01/2018 - "The biggest benefit from fidaxomicin treatment was shown in a cohort of patients with primary CDI infection demonstrating a low recurrence rate and significant reduction of fidaxomicin effectiveness in preventing a recurrence when treating patients with multiple rCDI."
01/01/2013 - "Fidaxomicin is less effective against infections caused by the Ribotype 027 strain, a virulent strain that is regularly encountered in the Netherlands. "
07/01/2021 - "Few studies have demonstrated the efficacy of fidaxomicin in the treatment of fulminant C lostridi oides difficile infection (CDI). "
02/01/2023 - "Recent changes in guidelines for managing Clostridioides difficile infections (CDI) have placed fidaxomicin as a first-line treatment. "

12/01/2022 - "Currently, fidaxomicin is the suggested treatment of initial and recurrent infection. "
01/01/2018 - "Among the treatments for non-multiply recurrent infections by C difficile, the highest quality evidence indicates that fidaxomicin provides a sustained symptomatic cure most frequently. "
05/01/2014 - "Fidaxomicin reduced the risk of both relapse (competing risks hazard ratio [HR], 0.40 [95% confidence interval {CI}, .25-.66]; P = .0003) and reinfection (competing risks HR, 0.33 [95% CI, 0.11-1.01]; P = .05). "
02/01/2012 - "Fidaxomicin was shown to have less frequency of recurrent infections. "
08/01/2013 - "Newer antibiotics such as fidaxomicin appear promising especially for the treatment of recurrent infection. "

11/01/2012 - "Safety and efficacy of fidaxomicin in the treatment of Clostridium difficile-associated diarrhea."
08/17/2018 - "Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial."
01/01/2018 - "Fidaxomicin is an antibacterial drug in clinical use for treatment of Clostridium difficile diarrhea. "
01/01/2015 - "Real-world experience is needed to determine whether fidaxomicin has value in patients with Clostridium difficile-associated diarrhea (CDAD) and certain risk factors. "
01/01/2015 - "Fidaxomicin Use and Clinical Outcomes for Clostridium difficile-Associated Diarrhea."

07/01/2013 - "With fidaxomicin, median TTROD was not significantly affected by presence of cancer (74 v 54 hours; log-rank P = .145). "
11/01/2014 - "The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer."
12/01/2013 - "Is fidaxomicin the drug of choice for treating Clostridium difficile-associated diarrhea in patients with cancer?"
10/01/2016 - "In patient subgroups with CDI at increased recurrence risk, fidaxomicin was cost-effective vs. vancomycin, and less costly and more effective in patients with cancer."
10/01/2016 - "Despite higher drug acquisition costs, fidaxomicin was dominant in the cancer subgroup (less costly and more effective) and cost-effective in the other subgroups, with incremental cost-effectiveness ratios vs. vancomycin ranging from €26,900 to €44,500. "